Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OSUR 
OraSure Technologies Inc (OSUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: OSUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.03% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.08M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 4 | Beta 0.27 | 52 Weeks Range 2.36 - 4.60 | Updated Date 08/29/2025 |
52 Weeks Range 2.36 - 4.60 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.17 | Actual -0.19 |
Profitability
Profit Margin -36.84% | Operating Margin (TTM) -55.35% |
Management Effectiveness
Return on Assets (TTM) -7.24% | Return on Equity (TTM) -12.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20167687 | Price to Sales(TTM) 1.75 |
Enterprise Value 20167687 | Price to Sales(TTM) 1.75 | ||
Enterprise Value to Revenue 0.15 | Enterprise Value to EBITDA 2.22 | Shares Outstanding 73137000 | Shares Floating 69481600 |
Shares Outstanding 73137000 | Shares Floating 69481600 | ||
Percent Insiders 4.91 | Percent Institutions 90.57 |
Upturn AI SWOT
OraSure Technologies Inc
Company Overview
History and Background
OraSure Technologies Inc. was founded in 1987 as STC Technologies. It has evolved from developing specimen collection devices to focusing on point-of-care diagnostics, particularly in infectious diseases and substance abuse testing. Notable milestones include the FDA approval of its OraQuick HIV self-test.
Core Business Areas
- Molecular Solutions: Focuses on developing and commercializing molecular collection kits for infectious disease and human genetics testing. This includes the ORAcollect Dx and ORAcollect RNA product lines.
- Infectious Disease: Provides rapid, point-of-care tests for infectious diseases, including HIV and HCV. OraQuick is a key product in this segment.
- Substance Abuse Testing: Offers oral fluid drug testing devices and laboratory services for detecting drug use.
Leadership and Structure
The leadership team includes Lisa Michels (CEO), Roberto Cuca (CFO), and key executives overseeing different business units. The organizational structure is functional, with departments focused on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- OraQuick HIV Self-Test: A rapid, over-the-counter HIV test that provides results in 20 minutes. It has significant market share in the self-testing segment. Competitors include at-home HIV test kits from other diagnostics companies and traditional laboratory testing services. Market share data is difficult to determine as they compete on a number of product offerings.
- ORAcollect Dx: DNA collection device used for molecular diagnostic testing. Competitors include other collection kit manufacturers and alternative sample collection methods. Market share data is difficult to determine as they compete on a number of product offerings.
- Intercept i2STAT: On-site oral fluid drug testing device, providing rapid results for substance abuse detection. Competitors include laboratory-based drug testing and other point-of-care drug testing devices. Market share data is difficult to determine as they compete on a number of product offerings.
Market Dynamics
Industry Overview
The diagnostics industry is driven by increasing demand for rapid, accurate, and accessible testing solutions. Point-of-care testing is a growing segment, fueled by advancements in technology and the need for faster results.
Positioning
OraSure is positioned as a leader in oral fluid-based diagnostics and point-of-care testing. Its competitive advantages include its patented technologies, established distribution network, and strong brand recognition in HIV self-testing.
Total Addressable Market (TAM)
The total addressable market for molecular diagnostics and infectious disease testing is estimated to be in the billions of dollars. OraSure is positioned to capture a portion of this TAM through its innovative products and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong brand recognition in HIV self-testing
- Patented oral fluid collection technology
- Established distribution network
- Focus on point-of-care diagnostics
- FDA-approved products
Weaknesses
- Reliance on a few key products
- Potential for competition from larger diagnostics companies
- Fluctuations in government funding for HIV testing programs
- Gross Profit Margin Fluctuations
- Debt Management
Opportunities
- Expansion into new markets and geographies
- Development of new diagnostic tests for other infectious diseases
- Partnerships with pharmaceutical companies and healthcare providers
- Increase sales due to opioid crisis
- Growth of personalized medicine
Threats
- Competition from established diagnostics companies
- Changes in regulatory landscape
- Technological advancements that could render its products obsolete
- Economic downturn
- Patent expirations
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Danaher Corporation (DHR)
- Thermo Fisher Scientific (TMO)
Competitive Landscape
OraSure is a smaller player compared to its larger competitors like Abbott and Danaher. It competes by focusing on niche markets, such as oral fluid-based diagnostics.
Major Acquisitions
CoreBiome, Inc.
- Year: 2020
- Acquisition Price (USD millions): 17.6
- Strategic Rationale: Expand into the microbiome testing market and grow OraSureu2019s portfolio into additional applications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, influenced by factors such as the demand for HIV self-testing and substance abuse testing products.
Future Projections: Analyst estimates suggest moderate revenue growth in the coming years, driven by new product launches and market expansion.
Recent Initiatives: Recent initiatives include expanding its molecular solutions business and pursuing partnerships to develop new diagnostic tests.
Summary
OraSure Technologies Inc. is a niche player in the diagnostics market with strengths in oral fluid-based testing and point-of-care solutions. Its reliance on a few key products and exposure to regulatory changes pose challenges. However, the company has opportunities to expand its product portfolio, grow into new markets, but needs to stabilize revenue and gross margins.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. Investment decisions should be made based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OraSure Technologies Inc
Exchange NASDAQ | Headquaters Bethlehem, PA, United States | ||
IPO Launch date 1986-11-12 | President, CEO & Director Ms. Carrie Eglinton Manner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 501 | Website https://www.orasure.com |
Full time employees 501 | Website https://www.orasure.com | ||
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company's products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is h
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.